A DELE M. G ULFO
Sparkle of Hope Gala Chair
Sparkle of Hope Gala Chair
VICTOR BULTO President, Novartis US Novartis Pharmaceuticals
ADELE M. GULFO Global President/Board Director Healthcare Sector President & CEO Biopharma Strategies & Insight Adele is a globally recognized healthcare executive, known for industry-leading clinical development and commercialization of the world’s most successful medicines at Pfizer, AstraZeneca, Viatris and Sumitomo Pharma. She most recently served as Chief Executive Officer, A dele is a globally recognized healthcare executive, known for industry-leading clinical development and commercialization of several of the world’s most successful medicines at Pfizer, AstraZeneca, and Sumitomo Pharma. She most recently served as the Chief Executive Officer, Biopharma Commercial Unit, for Sumitomo Pharma America, Inc. where she had oversight of the Company’s commercial and development portfolio of $1.2B+ across multiple therapeutic areas including, oncology, rare, urology, CNS and Women’s Health. Biopharma Commercial Unit, for Sumitomo Pharma America, Inc. [TSE:4506] where she led the organization to 46% revenue growth and delivered significant profit improvement across a diverse portfolio spanning oncology, rare disease, urology, neurology and women’s health. Ms. Gulfo previously served as Country Manager for Pfizer’s US biopharmaceutical businesses, including Specialty, Oncology, and Vaccines, which generated over $20B during her tenure. She was Pfizer’s President of Latin America ($4B business), where she led a team of over 4,000 colleagues across 24 countries and was President of Pfizer’s $12B+ US primary care business unit, comprised of over 5,000 employees across multiple therapeutic areas. Ms. Gulfo was Executive Vice President, Chief Strategy Officer, and Head of Global Commercial Development at Mylan, which is now Viatris Prior to joining Pfizer, she spent 9 years at AstraZeneca where she held executive roles in General Management, and Business Development. She ran the company’s Cardiovascular business unit where she led the successful launch of CRESTOR® (peak sales $6.6B) and secured a transformative partnership in diabetes. Before joining AstraZeneca, Ms. Gulfo planned and executed the commercial launch for LIPITOR®, the world’s most successful branded medicine with more than $125B in global sales over ~14.5 years. Prior to her time at Pfizer, Ms. Gulfo spent nine years at AstraZeneca where she held executive P&L roles in General Management and Business Development. She led the company’s Cardiovascular business unit spearheading the successful launch of CRESTOR® (peak sales $6.6B) and securing a transformative diabetes partnership with BMS. Earlier in her career, Ms. Gulfo planned and executed the commercial launch for LIPITOR®, the world’s most successful branded medicine, which achieved peak U.S. sales exceeding $13B. Ms. Gulfo previously served as Country Manager for Pfizer’s U.S. biopharmaceutical businesses, including Specialty, Oncology, and Vaccines, which generated over $20B during her tenure. She also served as President of Latin America, leading a $4B business with more than 4,000 colleagues across 24 countries, and as President and General Manager of Pfizer’s $12B+ U.S. primary care business unit, managing 5,000+ employees across multiple therapeutic areas. She later served as Executive Vice President, Chief Strategy Officer, and Head of Global Commercial Development at Viatris. E XECUT I VE B IO Adele is a globally recognized healthcare executive, known for industry-l commercialization of the world’s most successful medicines at Pfizer, Ast Pharma. She most recently served as Chief Executive Officer, Biopharma Commer America, Inc. [TSE:4506] where she led the organization to 46% revenue profit improvement across a diverse portfolio spanning oncology, rare women’s health. Adele has extensive public company board experience and has served on committees including Audit, Nominating and Governance, Compensation, and Investment. She currently serves as a director on EnPro Industries [NYSE: NPO], a leading industrial engineering firm that designs, develops and manufactures proprietary engineered products for use in markets such as semiconductor, nuclear, food, pharma and aerospace. From 2019 to 2023, she served on the board of Myovant [NYSE: MYOV] a company focused on Women’s Health and Prostate Cancer, which was acquired by Sumitomo Pharma in 2023. She served on the board of Bemis Company [NYSE: BMS] a global supplier of industrial packaging for five years, which merged with Amcor in 2019. She served on Medexus [TSX:MDP] for five years and currently serves on the Innovation Growth Board for Mass General Brigham, the largest hospital-based research enterprise in the US, with annual funding of more than $2B. Trained as a scientist, she has been awarded six U.S. patents on novel medication packaging and allergy treatments. She holds a Bachelor of Science degree in biology from Seton Hall University; an MBA with highest honors from Fairleigh Dickinson University; and studied post- graduate Molecular Biology and began her career at the University of Medicine and Dentistry of New Jersey (now Rutgers School of Biomedical Sciences). Ms. Gulfo has extensive public company board experience, having served on various committees, including Audit, Nominating and Governance, Compensation, and Investment. She currently serves on Enpro [NYSE:NPO], a leading industrial engineering firm that designs, develops, and manufactures proprietary engineered products for use in semiconductor, nuclear, pharma, and aerospace. She also serves on the boards of New Amsterdam Pharma [NASDAQ: NAMS], which focuses on cardiovascular disease and Tyra Biosciences [NASDAQ: TYRA], which specializes in oncology and rare disease. Previously, she served on Myovant [NYSE: MYOV], which was acquired by Sumitomo Pharma. She also served on the board of Bemis Company [NYSE: BMS] a global supplier of industrial and healthcare packaging until its acquisition by Amcor [NYSE: AMCR]. She served on Medexus [TSX:MDP] a Biopharma company with a portfolio across allergy, dermatology, hematology and rheumatology. She currently serves on the Innovation Growth Board for Mass General Brigham, the largest U.S. hospital-based research enterprise in with $2B+ in annual funding. Trained as a scientist, Ms. Gulfo has six U.S. patents. She earned a Bachelor of Science degree in Biology from Seton Hall University, an MBA with highest honors from Fairleigh Dickinson University, pursued post-graduate studies in Molecular Biology and began her career at the Rutgers School of Biomedical Sciences. Ms. Gulfo previously served as Country Manager for Pfizer’s U.S. biophar Specialty, Oncology, and Vaccines, which generated over $20B during President of Latin America, leading a $4B business with more than 4,000 co as President and General Manager of Pfizer’s $12B+ U.S. primary care employees across multiple therapeutic areas. She later served as Executiv Officer, and Head of Global Commercial Development at Viatris. Global President / − Healthcare Enterprise Strategy Leadership Board Experience □ Stra Global Markets □ Ta
Victor Bulto is President of Novartis US and reports to Novartis CEO Vas Narasimhan. As the US President, Victor is pursuing a bold strategy to reimagine medicine and deliver on the company’s responsibility to unlock the potential for helping patients in the world’s largest healthcare market. Prior to this role, Victor served as President, Novartis
Pharmaceuticals Corporation, leading the US pharmaceuticals business. He has been with Novartis for over 20 years and has broad, multi-national experience in the healthcare industry. He has worked across every therapeutic area at Novartis Pharmaceuticals and played critical roles in launching numerous products. He held various other positions at Novartis, including Head of the US Alcon Pharmaceuticals Franchise and Head of the Neuroscience Franchise for Region Europe, where he had responsibility for the overall strategy, growth and profitability of these businesses. Before joining Novartis, Victor was a medical device sales representative. Victor is driven by the pressing need to translate medicines to outcomes for broad patient populations and transform the patient experience to help mitigate the challenges people living with disease face in getting diagnosed, obtaining medicine, and staying on treatment within the complex US healthcare system. He has a strong track-record as a people-first leader with a focus on creating a culture where each individual can show up every day as their authentic self to best serve the interests of people living with disease. A lifelong learner, Victor has a master’s degree in Health Economics and Pharmaeconomics and a postgraduate degree in Pharmaceutical Marketing from Universitat Pompeu Fabra. He also received his Master’s in Business Administration from Esade. In 2019, Victor attended the Harvard Business School Advanced Management Program, Business Administration and Management, and from 2007-2008 he attended the postgraduate certificate program in leadership at Glasgow Caledonian University. Victor also holds a master’s degree in Chemical Engineering and a Bachelor of Science in Chemistry from the Institut Químic de Sarrià.
Made with FlippingBook - Online Brochure Maker